There is an urgent need for a pharmacological agent that can specifically and safely correct the shared metabolic pathology, ideally by acting at both central (e.g., controlling appetite and cravings) and peripheral (e.g., improving insulin sensitivity, reducing hepatic fat and inflammation) levels to support and enhance existing behavioral strategies, thereby lowering the risk of advanced liver disease development across metabolic and alcoholic etiologies
The toxin resembled glucagon, a hormone that raises blood sugar, so, scientists named it glucagon-like-peptide 1, or GLP-1. In the early 2000s, we got our first medical breakthrough with GLP-1, a drug called exenatide (Byetta) approved for the treatment of type 2 diabetes
If your levothyroxine dose changes, mention it to your Mounjaro prescriber, so they have a complete medication list
The shot is a quick way to get your B12 levels back to where they should be
Gallbladder symptoms develop, as tirzepatide has a lower biliary risk profile